Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Learn More
Banner

CAR-T Cell Therapy Development Service for Pancreatic Cancer

CAR-T Cell Therapy Development Service for Pancreatic Cancer

Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a groundbreaking approach in the fight against pancreatic cancer (PC). Alfa Cytology's CAR-T cell therapy development service involves optimizing CAR design, improving T-cell persistence and function, and identifying novel tumor-associated antigens. We are dedicated to enhance the efficacy and safety of CAR-T cell therapy for pancreatic cancer.

Overview of CAR-T Cell Therapy for Pancreatic Cancer

CAR-T cell therapy, which uses genetically engineered T-cells redirected to specific cancer-associated antigens to trigger potent cytotoxic activity, has emerged as a promising therapeutic strategy for a wide range of hematologic malignancies, and to date has been widely used as an individualized treatment. However, the food and drug regulatory agencies has not yet approved its use for the treatment of solid tumors. Nonetheless, CAR-T cell therapy remains a promising immunotherapeutic strategy for pancreatic cancer, a solid cancer that is resistant to standard tumor therapies.

Fig. 1 Isolation, engineering, and challenges of CAR T cell therapy in pancreatic adenocarcinoma (PDAC).Fig. 1 Isolation, engineering, and challenges of CAR T cell therapy in pancreatic adenocarcinoma (PDAC). (Akce M, et al, 2018)

Pre-clinical Studies on CAR-T Cell Therapy in Pancreatic Cancer

Researchers have conducted numerous studies on the application of CAR-T cells for PC therapy in animal or human cell line models with the aim of identifying suitable tumor-associated antigens (TAA), as well as evaluating the toxicity and efficacy of CAR-T cells, with exciting results.

Model Targeted Tumor Antigen Type of CAR-T Cells
In vitro and in vivo CEA and MSLN Dual receptor (anti-CEA and anti-MSLN) CAR-T cells
In vitro and in vivo MSLN Anti-MSLN CAR-T cells
In vivo CEA IL-18-secreting CAR-T cells
In vitro and in vivo CD70 Anti-CD70 CAR-T cells expressing CXCR1 and CXCR2
In vitro and in vivo Trop2 Anti-Trop2 CAR-T cells
In vitro and in vivo PD-1 PD1-Dap10-CD3zeta CAR-T cells
In vitro and in vivo NKG2D NKG2D CAR-T cells with deleted 4.1R protein
In vitro and in vivo MSLN CAR-T cells with ICOS
In vitro and in vivo ROR1 SCFAs—modified CAR-T cells

Our Services

Alfa Cytology's one-stop CAR-T cell therapy development service provides a comprehensive, integrated approach to preclinical research. The service covers all aspects of CAR-T cell therapy development, ensuring a streamlined and efficient process that overcomes the unique challenges posed by the pancreatic cancer tumor microenvironment.

Workflow of CAR-T Cell Therapy Development for Pancreatic Cancer

Target Antigen Discovery
Identification of specific TAAs expressed on pancreatic cancer cells through advanced genomic and proteomic approaches.

CAR Design and Engineering
Construction of CARs with optimized antigen-binding domains, co-stimulatory signals, and intracellular signaling motifs to enhance T-cell activation and persistence.

T-Cell Transduction and Expansion
Genetic modification of patient-derived T-cells using viral or non-viral vectors to express CARs, followed by ex vivo expansion to achieve a therapeutically relevant cell dose.

In Vitro Efficacy Testing
Assessment of CAR-T cell cytotoxicity, proliferation, and cytokine production against pancreatic cancer cell lines in controlled laboratory settings.

In Vivo Preclinical Studies
Evaluation of the anti-tumor efficacy and safety of CAR-T cells in animal models of pancreatic cancer, including assessments of tumor regression, survival benefit, and off-target effects.

Safety and Toxicity Assessment
Comprehensive evaluation of potential toxicities, including cytokine release syndrome (CRS) and off-target cytotoxicity, to ensure the safety profile of the CAR-T cells.

Why Choose Us?

Tailored Solutions

Advanced Technology

Professional Expertise

Collaborative Approach

Alfa Cytology's CAR-T cell therapy development services for pancreatic cancer offer a comprehensive and integrated approach to preclinical research. We employ cutting-edge technologies and innovative strategies to overcome the unique challenges of pancreatic cancer and ensure the development of highly effective and safe CAR-T cell therapies. For more information or to establish a partnership, please contact us directly.

References

  1. Akce M, et al. The Potential of CAR T Cell Therapy in Pancreatic Cancer. Front. Immunol. 2018, 9:2166.
  2. Czaplicka A, et al. Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence. Cells. 2024, 13(1):101.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.